Missing the forest (plot) for the trees? A critique of the systematic review in tobacco control by Rosen, Laura J et al.
Rosen et al. BMC Medical Research Methodology 2010, 10:34
http://www.biomedcentral.com/1471-2288/10/34
Open Access CORRESPONDENCE
BioMed  Central
© 2010 Rosen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Correspondence Missing the forest (plot) for the trees? A critique of 
the systematic review in tobacco control
L a u r aJR o s e n * 1, Michal Ben Noach2 and Elliot Rosenberg3
Abstract
Background: The systematic review (SR) lies at the core of evidence-based medicine. While it may appear that the SR 
provides a reliable summary of existing evidence, standards of SR conduct differ. The objective of this research was to 
examine systematic review (SR) methods used by the Cochrane Collaboration ("Cochrane") and the Task Force on 
Community Preventive Services ("the Guide") for evaluation of effectiveness of tobacco control interventions.
Methods: We searched for all reviews of tobacco control interventions published by Cochrane (4th quarter 2008) and 
the Guide. We recorded design rigor of included studies, data synthesis method, and setting.
Results: About a third of the Cochrane reviews and two thirds of the Guide reviews of interventions in the community 
setting included uncontrolled trials. Most (74%) Cochrane reviews in the clinical setting, but few (15%) in the 
community setting, provided pooled estimates from RCTs. Cochrane often presented the community results 
narratively. The Guide did not use inferential statistical approaches to assessment of effectiveness.
Conclusions: Policy makers should be aware that SR methods differ, even among leading producers of SRs and among 
settings studied. The traditional SR approach of using pooled estimates from RCTs is employed frequently for clinical 
but infrequently for community-based interventions. The common lack of effect size estimates and formal tests of 
significance limit the contribution of some reviews to evidence-based decision making. Careful exploration of data by 
subgroup, and appropriate use of random effects models, may assist researchers in overcoming obstacles to pooling 
data.
Background
At the core of evidence-based medicine, with its hierar-
chy of evidence and guidelines, lies the systematic review
(SR). The potential of the SR to "make order out of scien-
tific chaos" [1] has attracted researchers, policy makers,
journal editors, and funders [2]. The simplicity of the core
idea - to search for all relevant articles of a defined nature,
followed by quantitative synthesis when possible has
strong inherent appeal. Like evidence-based medicine,
the more recent evidence-based public health also relies
heavily on the systematic review. But attempting to accu-
rately summarize evidence in public health has particular
challenges.
One major challenge for the reviewer of public health
interventions concerns inclusion criteria for original
studies. Reviews in medicine often include only random-
ized controlled trials (RCTs). In public health, however,
RCTs may be more difficult to perform [3]. Legislation
and taxation, two classic public health approaches, which
are implemented on a population-wide basis, are not eas-
ily amenable to assessment by randomized or even non-
randomized controlled methods. Other public health
interventions are community-based and are also often
evaluated without the benefit of a randomized approach.
Thus, in deciding which level of evidence to include in
SRs of public health intervention effectiveness, reviewers
are presented with a difficult choice: restrictive inclusion
criteria may exclude all or most of the existing evidence,
thereby potentially missing true effects, while more lib-
eral inclusion criteria may include studies with weaker,
bias-prone study designs which may incorrectly show
effectiveness.
A second challenge pertains to information synthesis.
In medicine, the dose of a given medication or the details
of a procedure may differ between studies, yet the inter-
ventions may be more similar than different. In public
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health, there is a greater possibility for heterogeneity
between interventions, and the differences between their
interventions may exceed the similarities. Hence the
increased difficulty in deciding about the methods of syn-
thesis of the findings of the various studies included in
SRs.
Both of these challenges have been discussed previ-
ously [3]. However, no single solution has received gen-
eral acceptance.
This paper compares the methods used in producing
SRs of tobacco control, which were performed by the
Cochrane Collaboration ("Cochrane") [4]and the Task
Force on Community Preventive Services ("the Guide")
[5]. The Cochrane Collaboration is "dedicated to making
up-to-date, accurate information about the effects of
healthcare readily available worldwide. It produces and
disseminates systematic reviews of healthcare interven-
tions and promotes the search for evidence in the form of
clinical trials and other studies of interventions." [4]
The Guide's mandate is to "recommend interventions
to improve the performance of healthcare systems; inter-
ventions implemented in community settings such as
schools, worksites, and community organizations, and
interventions applied to entire communities." [[5], p. ix]
In order to do this, the Guide develops conceptual models
linking determinants of public health problems, interven-
tions for change, intermediate outcomes such as behav-
ioral change, and health. Understanding the "big picture"
of cause and effect drives Guide decisions about which
interventions to research; then the Guide performs "sys-
tematic review(s) to provide scientific evidence of the
effectiveness of interventions. Recommendations are
explicitly linked to this evidence and are therefore evi-
dence-based." [[5], P. xxvi].
Consequently, both Cochrane and the Guide produce
systematic reviews, though only the Guide consistently
produces recommendations.
Cochrane is an international organization, while the
work of the Task Force is based in, and geared towards,
the United States. Cochrane reviews are performed by
individual researchers throughout the world, subject to
the rigorous demands of a Cochrane editorial review
board, while Guide reviews are commissioned and oper-
ate under the auspices of evidence-based practice centers
in the United States.
SRs from both organizations are used in the United
States and internationally (US Department of Health and
Human Services 2004, US Department of Health and
Human Services 2004 2006, Agency for Healthcare
Research Quality 2008, National Institutes of Health
2008, World Health Organization 2008, National Institute
for Clinical Excellence 2008, Institute of Medicine 2008)
for policy, reimbursement, and guideline setting, and are
an important part of the evidence base for tobacco con-
trol policy.
The specific objectives of the present study were to (a)
determine whether inclusion criteria for rigor of study
design, and synthesis methods, differed between the two
organizations; (b) to determine whether level of rigor dif-
fered by study setting (clinic or community), and (c) to
explore how these differences may impact the utility of
the reviews for health policymakers.
Methods
We examined all reviews published by Cochrane
(Cochrane 2008 4th quarter, online) [4] the Guide, [5-7]
pertaining to tobacco control. Each review was catego-
rized by the level of design of the included studies, set-
ting, and method of data synthesis. All information was
extracted independently by two authors of this paper (LR
and MBN). Disagreements were resolved by discussion.
Settings were defined as Clinical (interventions aimed
at individuals in a clinical setting), Clinical system (inter-
ventions involving the healthcare system, such as subsi-
dies for cessation medications or provider training),
Community (interventions aimed at individuals in a com-
munity setting), or Mixed (trials involving interventions
in two or more of the above).
T o each SR, we assigned the level of evidence of the
study with the least rigorous design that was included in
the review. Level 1 indicated that all original studies
included in the review used a randomized design. Level 2
indicated that at least one of the studies was a quasi-ran-
domized study, and all studies were either quasi-random-
ized or randomized. Level 3 indicated that there was at
least one non-randomized controlled trial in the set of
original studies, and that all studies were either random-
ized, quasi-randomized, or non-randomized controlled
trials. Level 4 indicated that there was at least one
included original study which had an uncontrolled design
(before-and-after, or interrupted time series), and that all
studies were either randomized or quasi-randomized or
controlled or uncontrolled.
We categorized the methods of synthesis used in the
SRs as "meta-analysis," "median," or "narrative." We used
the term "meta-analysis" to denote reviews in which data
were synthesized using a standard statistical technique
for combining outcomes. In those reviews, estimates of
the intervention effect (in terms of odds ratios or relative
risks) were presented with a measure of statistical signifi-
cance (p-value). Those reviews which were summarized
using the "median" method provided the median of the
set of estimated effects from the individual studies, with-
out an accompanying p-value. Both the meta-analysis and
median methods are considered quantitative methods of
synthesis in this paper. Reviews summarized with the
narrative method of synthesis provided descriptive sum-Rosen et al. BMC Medical Research Methodology 2010, 10:34
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maries of results, without an estimate of an overall inter-
vention effect.
Results
Cochrane
We located the following 49 reviews, of which 46 were
completed:
C1: Acupuncture and related interventions for smok-
ing cessation.
C2: Antidepressants for smoking cessation
C3: Anxiolytics for smoking cessation
C4: Aversive smoking for smoking cessation
C5: Biomedical risk assessment as an aid for smoking
cessation
C6: Cannabinoid type 1 receptor antagonists (rimona-
bant) for smoking cessation C7: Clonidine for smoking
cessation
C8: Community interventions for preventing smoking
in young people
C9: Community interventions for reducing smoking
among adults
C10: Community pharmacy personnel interventions
for smoking cessation
C11: Competitions and incentives for smoking cessa-
tion
C12: Enhancing partner support to improve smoking
cessation
C13: Exercise interventions for smoking cessation
C14: Family and carer smoking control programmes
for reducing children's exposure to environmental
tobacco smoke
C15: Family-based programmes for preventing smok-
ing by children and adolescents
C16: Group behaviour therapy programmes for smok-
ing cessation
C17: Healthcare financing systems for increasing the
use of tobacco dependence treatment
C18: Hypnotherapy for smoking cessation
C19: Impact of tobacco advertising and promotion on
increasing adolescent smoking behaviours
C20: Individual behavioural counselling for smoking
cessation
C21: Interventions for preoperative smoking cessation
C22: Interventions for preventing tobacco sales to
minors
C23: Interventions for preventing tobacco smoking in
public places
C24: Interventions for promoting smoking cessation
during pregnancy
C25: Interventions for smokeless tobacco use cessation
C26: Interventions for smoking cessation in hospital-
ised patients
C27: Interventions for tobacco cessation in the dental
setting
C28: Interventions for waterpipe smoking cessation
C29: Interventions to reduce harm from continued
tobacco use
C30: Lobeline for smoking cessation
C31: Mass media interventions for preventing smoking
in young people
C32: Mass media interventions for smoking cessation
in adults
C33: Mecamylamine (a nicotine antagonist) for smok-
ing cessation C34: Nicobrevin for smoking cessation
C35: Nicotine receptor partial agonists for smoking
cessation
C36: Nicotine replacement therapy for smoking cessa-
tion
C37: Nursing interventions for smoking cessation
C38: Opioid antagonists for smoking cessation
C39: Physician advice for smoking cessation
C40: Psychosocial interventions for smoking cessation
in patients with coronary heart disease
C41: Quit and Win contests for smoking cessation
C42: Relapse prevention interventions for smoking ces-
sation
C43: School-based programmes for preventing smok-
ing
C44: Self-help interventions for smoking cessation
C45: Silver acetate for smoking cessation
C46: Telephone counselling for smoking cessation
C47: Tobacco cessation interventions for young people
C48: Training health professionals in smoking cessa-
tion
C49: Workplace interventions for smoking cessation
There were 44 completed reviews in the Cochrane
library's Tobacco Addiction Groupc1-c23, c25-c27, c29, c31-c32,
c34-c40, c42-c49 (one of thesec23 was temporarily withdrawn;
an earlier version was therefore used in the present analy-
sis), three planned reviews which were not performed
because no original studies were found for inclusion
(these reviews were excluded from further analyses),c28,
c30, c34 one smoking-related review in the Pregnancy
Group, c24 and one smoking-related review in the Heart
Group.c41 The studies had been carried out in Clinical
settings (19/46, 41.3%),c1-c7, c18, c21, c26, c27, c33, c35-c40, c45
Clinical systems (2/46, 4.3%),c17, c48 Community (13/46,
28.3%),c8-c12, c19, c22, c23, c31, c32, c41, c43, c49 and Mixed settings
(eg, settings for different included studies were different,
or a specific intervention took place both in the clinical
and community setting) (12/46, 26.1%).c13-c16, c20, c24, c25,
c29, c42, c44, c46, c47 Most reviews included designs at Level 1
(26/46, 56.5%).c1-c7, c10, c12, c13, c15, c16, c18, c21, c25, c33, c35-c38, c40,
c42-c45, c48 A fair number included designs at Levels 2 or 3
(14/46, 30.4%),c8, c9, c11, c14, c20, c24, c26, c27, c29, c31, c39, c41, c46, c47
while a minority of reviews included designs at Level 4 (6/
46, 13.0%). c17, c19, c22, c23, c32, c49 Results were synthesizedRosen et al. BMC Medical Research Methodology 2010, 10:34
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using meta-analysis in most (30/46, 65.2%) of reviews,c1-
c7, c11, c12, c16-c18, c20, c24-c27, c29, c35-c40, c42-c47 with the remain-
der (16/46, 34.8%) summarized using a narrative
approach.c8-c10, c13-c15, c19, c21-c23, c31-c33, c41, c48, c49 
Tables 1, 2, 3 present the distributions of the SRs by
level of study design, methods of data synthesis and set-
ting. The information is illustrated in Figure 1 as Quorum
Trees [8]. Of the 19 Cochrane reviews of interventions in
clinical settings, most (16/19, 84.2%) included Level 1
design types, while the remainder (3/19, 15.8%) included
Level 2 design types. Meta analysis was used to synthesis
the data in most cases (17/19, 89.5%). Most (14/19,
73.7%) reported statistically pooled results from RCTs,
and 89.5% (17/19) reported pooled results from either
RCTs or CTs.
Of the 13 reviews of interventions which took place in
the community setting, design types were split between
Level 1 (3/13, 23.1%), Level 2 or 3 (5/13, 38.5%), and Level
4 (5/13, 38.5%). Most (10/13, 76.9%) reviews of commu-
nity interventions used the narrative approach for synthe-
sis. Few (2/13, 15.4%) reported pooled results from RCTs,
or from RCTs or CTs (3/13, 23.1%).
The Guide
The Guide conducted 21 SRs which formed the basis for
their recommendations [5-7]. These are listed below:
G1: Increase unit price
G2:Mass media education campaigns in combination
G3:Restricting minor's access: Community mobiliza-
tion plus other
G4:Laws directed at retailers (alone)
G5:Laws directed at minor's purchase, possession, use
(alone)
G6:Enforcement (alone)
G7:Retailer education with enforcement (alone)
G8:Retailer education without enforcement
G9:Community education regarding Minors' access
(alone)
G10:Increase unit price
G11:Reduce costs
G12:Telephone plus multicomponent
G13:Mass media education plus other
G14:Mass media education - cessation
G15:Mass media education - contests
G16:Healthcare provider reminder system
G17:Healthcare provider reminder plus provider edu-
cation
G18:Healthcare provider education alone
G19:Healthcare provider feedback
G20:Smoking bans
G21:Community education regarding environmental
tobacco smoke in the home
Three reviews lacked original studies and were
excluded from further analysis, g5, g7, g9 leaving a total of
18 completed reviews. Twelve Guide reviews (66.7%)
concerned interventions taking place entirely in the com-
munity, g1-g4, g6, g8, g10, g13-g15, g20, g21 five (27.8%) concerned
Table 1: Distribution of reviews by reviewer, setting, and level of study design
Level* Setting**
N (%)
Clinical Clinical System Community Mixed Total
COCHRANE
Level 1 16 (84) 1 (50) 3 (23) 6 (50) 26
Level 2 3 (16) 0 (0) 0 (0) 4 (33) 7
Level 3 0 (0) 0 (0) 5 (38) 2 (16) 7
Level 4 0 (0) 1 (50) 5 (38) 0 (0) 6
All levels 19 (100) 2 (100) 13 (100) 12 (100) 46
GUIDE
Level 1 0 (0) 0 (0) 4 (33) 0 (0) 4
Level 2 0 (0) 0 (0) 0 (0) 0 (0) 0
Level 3 0 (0) 0 (0) 0 (0) 1 (100) 1
Level 4 0 (0) 5 (100) 8 (67) 0 (0) 13
All levels 0 (0) 5 (100) 12 (100) 1 (100) 18
* Level: Level 1 (only RCTs included in review), Level 2 (At least one quasi-randomized study included in review), Level 3 (At least one 
controlled trial included in review), Level 4 (At least one non-controlled trial, such as interrupted time series, included in review).
**Setting: Clinical (interventions aimed at individuals in a clinical setting), Clinical system (interventions involving the healthcare system, such 
as subsidies for cessation medications or provider training), Community (interventions aimed at individuals in the community), or Mixed 
(included trials involving interventions in two or more of the above).Rosen et al. BMC Medical Research Methodology 2010, 10:34
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interventions within clinical systems, g11, g16-g19 and one
(5.6%) took place in a mixed environment. g12
Four included studies with Level 1 designs, g6, g8, g15, g21
one had Level 3 design, g12 and thirteen included Level 4
designs (72.2%).g1-g4, g10-g11, g13-g14, g16-g20 The majority (16/
18, 88.9%)g1-g4, g6, g8, g10-g13, g16-g21 were synthesized using
the median, and a few (2/18, 11.1%) g14, g15 were synthe-
sized using the narrative technique.
Of the 12 Guide reviews which took place in the com-
munity, one third (4/12) included Level 1 designs and two
Table 2: Distribution of reviews by reviewer, setting, and method of data synthesis
Synthesis 
Method*
Setting**
N (%)
Clinical Clinical System Community Mixed All
COCHRANE
Meta-analysis 17 (89) 1 (50) 3 (23) 9 (75) 30
Median 0 (0) 0 (0) 0 (0) 0 (0) 0
Narrative 2 (11) 1 (50) 10 (77) 3 (25) 16
All levels 19 (100) 2 (100) 13 (100) 12 (100) 46
GUIDE
Meta-analysis 0.0 (0) 0 (0) 0 (0) 0 (0) 0
Median 0.0 (0) 5 (100) 10 (83.3) 1 (100) 16
Narrative 0.0 (0) 0 (0) 2 (16.7) 0 (0) 2
All levels 0.0 (0) 5 (100) 12 (100) 1 (100) 18
* Synthesis Method: Meta-analysis (indicating a pooled statistic), calculation of the median (median of effect sizes taken without any 
accompanying p-value), or narrative.
** Setting: Clinical (interventions aimed at individuals in a clinical setting), Clinical system (interventions involving the healthcare system, 
such as subsidies for cessation medications or provider training), Community, or Mixed (included trials involving interventions in two or more 
of the above).
Table 3: Distribution of reviews by reviewer, setting, and methodological criteria
Combined 
methodological 
criteria*
Setting**
N (%)
Clinical Clinical System Community Mixed All
COCHRANE
RCTs with pooling 14 (74) 0 (0) 2 (15) 4 (33) 20
RCTs/CTs with 
pooling
3 (16) 0 (0) 1 (8) 5 (42) 9
Other 2 (11) 2 (100) 10 (77) 3 (25) 17
All levels 19 (100) 2 (100) 13 (100) 12 (100) 46
GUIDE
RCTs with pooling 0 (0) 0 (0) 3 (25) 0 (0) 3
RCTs/CTs with 
pooling
0 (0) 0 (0) 0 (0) 1 (100) 1
Other 0 (0) 5 (100) 9 (75) 0 (0) 14
All levels 0 (0) 5 (100) 12 (100) 1 (100) 18
* Combined methodological criteria: RCTs with pooling (Randomized controlled trials only, with quantitatively pooled results), RCTS/CTs with 
pooling (Randomized controlled trials or Controlled Trials only, with quantitatively pooled results), Other (any study design, any type of 
synthesis)
** Setting: Clinical (interventions aimed at individuals in a clinical setting), Clinical system (interventions involving the healthcare system, 
such as subsidies for cessation medications or provider training), Community, or Mixed (included trials involving interventions in two or more 
of the above).Rosen et al. BMC Medical Research Methodology 2010, 10:34
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thirds (8/12) included Level 4 designs. Most (10/12,
83.3%) were summarized using a median, while the
remainder (2/12, 16.7%) were summarized narratively. Of
the 5 Guide reviews which took place in the clinical sys-
tem setting, all were Level 4 designs and were summa-
rized using a median.
Discussion
Our study illuminates differences in conduct of SRs on
tobacco control between Cochrane and the Guide, as well
as differences in levels of rigor used for study of interven-
tions conducted in the clinical versus the community set-
tings. These findings support recent statements regarding
standards of SR conduct in medical and public health set-
tings [9]. In a departure from other work [3] on the topic,
it quantifies empirical use of different approaches to
study design inclusion criteria and methods of informa-
tion synthesis.
In the community setting, Cochrane reviews were less
likely than Guide reviews to include uncontrolled trials
(Cochrane: 38%, Guide: 67%). Findings from Cochrane
reviews were quantitatively synthesized less frequently
than were findings from Guide reviews (Cochrane: 23%,
Guide: 83%).
Comparisons between clinical and community settings
were only possible for the Cochrane reviews, as the Guide
did not assess interventions which take place in clinical
settings [5]. Nearly all (84%) of the Cochrane reviews on
clinical interventions included only RCTs, while a just
one quarter of its SRs of community-based interventions
did so. Most Cochrane SRs of clinical interventions uti-
lized pooled estimates of RCTs (74%), while the majority
of SRs of community interventions did not (83%,).
The preference for controlled over uncontrolled trials
found in community-based Cochrane reviews (62%) ver-
sus community-based Guide reviews (33%) may reflect
the continued influence of the vision of Archie Cochrane,
who called in 1979 for "assembly of a critical summary, of
all... relevant randomized controlled trials." While recent
Cochrane statements support this vision [10], other dec-
larations are more consistent with the fact that most
(77%) of Cochrane community-based SRs were not
Figure 1 Quorum trees of Cochrane and Guide systematic reviews by intervention setting and design rigor.Rosen et al. BMC Medical Research Methodology 2010, 10:34
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restricted to RCTs. The website of the Tobacco Addiction
Group [11] includes this statement: "Reviews will, in gen-
eral, be restricted to randomized or quasi-randomized
studies unless randomization is likely to be impractical for
the intervention studied, in which case Controlled Before
and After studies and Time Series studies may also be con-
sidered." Declarations by the Health Promotion and Pub-
lic Health (HPPH) Field [12], which became a Cochrane
group in 2007, stand in stark contrast to the original
vision: "The HPPH Field does not contend that all health
promotion and public health interventions must be justi-
fied by randomized controlled trials ... The criteria used to
select studies should primarily reflect the questions being
answered in the review, as opposed to any predetermined
hierarchy." While this group does not directly influence
the editorial policy of the Tobacco Addiction Group,
some population-based tobacco control interventions
may come under its purview in the future.
Our findings identify two main limitations that may
hinder the evidence-based policymaker in prioritizing
interventions aimed at controlling tobacco use. The first
relates to the assessment of effectiveness and the second
to the assessment of effect magnitude.
Several issues affect the assessment of effectiveness of
interventions. First, the synthesis of information by the
narrative technique, used frequently by Cochrane, does
not provide quantitative assessment of effectiveness.
Cochrane's use of the narrative review is generally explic-
itly justified by statistical considerations: either difficul-
ties in synthesizing data from cluster randomized trialsc10
or heterogeneity. c8, c9, c13, c14, c19, c21, c22, c23, c31, c32, c41, c49
Difficulties in synthesis due to clustering should not
pose a problem in the future, as appropriate statistical
software such as RevMan™ is now available [13]. Hetero-
geneity [10] is a more complex issue. Heterogeneity can
be "clinical" (referring to characteristics of the population
or the intervention), "methodological" (referring to differ-
ences in methods used in the different studies), or "statis-
tical" (referring to differences in the direction or
magnitude of the results). It is always important to
explore differences in results by using subgroup analyses.
Sometimes the reasons for differences in results are due
to clinical or methodological differences between the tri-
als. In those cases, in may be best to present statistical
summaries by subgroup. Heterogeneity of the results
explained by methodological differences may indicate
bias. When heterogeneity is present and cannot be
explained by clinical or methodological factors, it may be
appropriate to use a random effects, rather than fixed
effects, model. While the fixed effects approach asks the
question "What is the best estimate of the (one) true
effect of the intervention?" the random effects model asks
a different question: "What is the average effect of the
intervention, in its different forms and over different tar-
get populations?" Even in situations where the first ques-
tion is irrelevant (if it is assumed that different forms of
an intervention have different levels of effectiveness in
different populations, and so a single true effect does not
exist), the second question may be of substantial interest
to policy makers. RevMan and other meta analytic pro-
grams have options for running random effects as well as
other models, and reviewers should consider their use,
particularly when significant heterogeneity is present.
Assessment of effectiveness performed by the Guide is
problematic for a different reason. The median synthesis
technique employed has no accompanying statistical
assessment (p-value). Thus, these reviews lack the com-
mon denominator of effectiveness used as the statistical
basis for all of evidence-based medicine. The Guide [5]
states that when synthesizing results, it prefers "simplicity
of calculation." A publication by Task Force members [3]
noted that this decision was part of a trade-off which
allowed many reviews to be done, "despite serious defi-
ciencies in reporting in primary studies." They predict
that future editions of the Guide will include more meta-
analyses.
Related challenges exist with respect to assessment of
effect magnitude. Reviews summarized narratively do not
provide point estimates of effectiveness. Estimates of
effect magnitude from reviews which are quantitatively
synthesized, which include both randomized and non-
randomized trials, and which are not explored by sub-
group, may be difficult to interpret. Previous work has
shown that estimates of benefit derived by reviews which
included only randomized trials show less benefit than
those from reviews which included less rigorous study
designs [14]. The lack of assessment of effectiveness and
effect magnitude lessen the quality of the information
currently delivered to the policy maker.
One possible solution, to overcome the problems due to
weaker or different study designs, as well as different lev-
els of quality of implementation (such as high drop-out
rates or known biases) of some community-based studies,
would be to routinely stratify analyses by methodological
rigor and/or quality of conduct of included studies. Com-
parisons of effect sizes for the same type of intervention,
under different conditions of study design and conduct
quality, would then be possible (assuming sufficient
quantity and variety of original studies in the SRs).
Exploring differences in study results as a function of dif-
ferences in methodological rigor and/or implementation
quality of the original studies could contribute to the cur-
rent discussion of how best to perform SRs of interven-
tions in community settings.
This report is limited in several ways. Issues relating to
external validity, essential for estimating potential popu-
lation impact [15], are not investigated. We could not
address the effects of methodological rigor on conclu-Rosen et al. BMC Medical Research Methodology 2010, 10:34
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sions, because the topics of the individual studies dif-
fered. (That subject is more fully explored in a separate
paper, and is limited to the seven pairs of studies regard-
ing similar topics [16].) Further, analyses are limited to
SRs done by Cochrane and the Guide. Though we are
unable to infer findings of this study to other SRs on
tobacco control interventions, the issues raised regarding
assessment and estimation of effectiveness are likely to be
relevant in other SRs and public health topics.
Conclusions
Policy makers should be aware that SR methods differ,
even among leading producers of SRs, and among set-
tings studied. The traditional SR approach of using
pooled estimates from RCTs is employed frequently for
clinical but infrequently for community-based interven-
tions. The common lack of effect size estimates and for-
mal tests of significance limit the contribution of some
reviews to evidence-based decision making. Careful
exploration of data by subgroup, and appropriate use of
random effects models, may assist researchers in over-
coming obstacles to pooling data.
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